Leydig cell tumors represent about 3% of all testicular neoplasms. Actually no specific pathologic criteria has really distinguished the benign from the malignant tumors which represent about 11% of the cases. The presence of metastases is the only unequivocal criteria of malignancy. Authors present a rare Leydigoma case with gynecomastia. Clinical, diagnostical and most of all therapeutical aspects are discussed reconfirming the role of the orchifuniculectomy in T1 N0 M0 stage.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Even though Leydig cell tumor (LCT) represents the most common neoplasia among testicular sex cord-stromal tumors (SCSTs), it is a rare condition, comprising 1-2% of all testicular tumors, with a 10% risk of malignancy most commonly located in retroperitoneal lymph nodes. LCTs may demonstrate various clinical manifestations - from asymptomatic intratesticular swelling through nonspecific symptoms such as loss of libido, impotence or infertility, up to feminizing or virilizing syndromes due to hormonal activity of the tumor. This article presents a case of Leydig cell tumor that was associated with azoospermia what have rarely been reported worldwide.
View Article and Find Full Text PDFGetah virus triggers ROS-mediated autophagy in mouse Leydig cells.
Front Microbiol
January 2025
College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Introduction: Getah virus (GETV) is a zoonotic virus transmitted via a mosquito-vertebrate cycle. While previous studies have explored the epidemiology and pathogenicity of GETV in various species, its molecular mechanisms remain largely unexplored.
Methods: This study investigated the impact of GETV infection and associated molecular mechanisms on reactive oxygen species (ROS) and autophagy levels in mouse Leydig cells both and .
Successful management of Leydig Cell Tumor in a 65-year-Old patient: A rare case report.
Urol Case Rep
January 2025
Faculty member, Faculty of Medicine, Pathology Department, Damascus University, Damascus, Syrian Arab Republic.
Leydig cell tumors (LCTs) are rare testicular neoplasms, representing 1-3% of all testicular tumors. A 65-year-old male presented with a painless left scrotal mass. Ultrasound revealed a 61 × 53 × 35 mm tumor with heterogeneous echogenicity and abundant blood supply.
View Article and Find Full Text PDFTransferrin Receptor 2 in Canine Testicular Tumors: An Emerging Key Role in Seminomas.
Animals (Basel)
January 2025
Department of Biology, University of Naples Federico II, 80126 Naples, Italy.
Transferrin Receptor 2 (TfR2) is a homolog of Transferrin Receptor 1 (TfR1), involved in regulating intra and extracellular iron levels. Altered iron pathways have been associated with cancer onset and progression; however, their role in canine tumors remains poorly explored. This study investigated TfR2 immunohistochemical expression in non-neoplastic canine testis for the first time and in the most common types of canine testicular tumors: intratubular seminomas (ITSEMs), diffuse seminomas (DSEMs), Leydig cell tumors (LCTs), and Sertoli cell tumors (SCTs).
View Article and Find Full Text PDFA determination of the main regulators of necroptosis in testicular tissue under different heat stresses.
J Mol Histol
January 2025
Department of Histology and Embryology, Faculty of Veterinary Medicine, Sivas Cumhuriyet University, Sivas, Türkiye.
Although minimal increases in testicular temperature can compromise spermatogenesis and lead to fertility-related problems, the basic mechanism involved in germ cell destruction as a response to heat stress is still unclear. However, necroptosis is known to regulate a number of physiological and pathological events. This study investigated the role of RIPK1/RIPK3 and MLKL, the main regulators of necroptosis, against different heat stresses in testis tissue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!